Yushuang Zheng1, Wei Liu2, Lingchuan Guo3, Xianghong Yang4. 1. Department of Pathology, Shengjing Hospital of China Medical University, Shengyang 110004 China; Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu, China. 2. Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu, China. 3. Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu, China. Electronic address: geqohr@163.com. 4. Department of Pathology, Shengjing Hospital of China Medical University, Shengyang 110004 China. Electronic address: xianghyang1968@163.com.
Abstract
BACKGROUND: The clinical significance of miR-203 and its prognostic value have not been investigated in gastric cancer. METHODS: We assessed miR-203 expression in 141 gastric cancer samples and 141 paired non-cancerous samples by real-time PCR and calculated using the 2-ΔΔCt method. Differences between groups were examined for statistical significance by Student's t-test. Survival curves were computed by the Kaplan-Meier method, and differences between survival curves were compared by the log rank test. RESULTS: The expression of miR-203 was significantly lower in gastric cancer samples compared to non-cancerous samples (P<0.0001). Low miR-203 expression was found to be closely correlated with advanced stage (p=0.005), and lymph node involvement (p=0.009). Kaplan-Meier analysis with the log-rank test indicated that low miR-203 expression had a significant impact on overall survival (39.4% vs. 62.5%; P=0.043) and progression-free survival (32.5% vs. 58.6%; P=0.023). Furthermore, multivariate analysis revealed that miR-203 expression level was independent prognostic factors for overall survival (HR=2.73, 95% CI: 1.69-8.91; P=0.01), as well as progression-free survival (HR=4.19, 95% CI: 2.91-10.12; P=0.005). CONCLUSION: Our data validate an important clinical significance of miR-203 in gastric cancer, and reveal that it might be a potential prognostic factor for gastric cancer. Large- scale and long-term follow-up studies are needed to confirm the significance of miR-203 in gastric cancer.
BACKGROUND: The clinical significance of miR-203 and its prognostic value have not been investigated in gastric cancer. METHODS: We assessed miR-203 expression in 141 gastric cancer samples and 141 paired non-cancerous samples by real-time PCR and calculated using the 2-ΔΔCt method. Differences between groups were examined for statistical significance by Student's t-test. Survival curves were computed by the Kaplan-Meier method, and differences between survival curves were compared by the log rank test. RESULTS: The expression of miR-203 was significantly lower in gastric cancer samples compared to non-cancerous samples (P<0.0001). Low miR-203 expression was found to be closely correlated with advanced stage (p=0.005), and lymph node involvement (p=0.009). Kaplan-Meier analysis with the log-rank test indicated that low miR-203 expression had a significant impact on overall survival (39.4% vs. 62.5%; P=0.043) and progression-free survival (32.5% vs. 58.6%; P=0.023). Furthermore, multivariate analysis revealed that miR-203 expression level was independent prognostic factors for overall survival (HR=2.73, 95% CI: 1.69-8.91; P=0.01), as well as progression-free survival (HR=4.19, 95% CI: 2.91-10.12; P=0.005). CONCLUSION: Our data validate an important clinical significance of miR-203 in gastric cancer, and reveal that it might be a potential prognostic factor for gastric cancer. Large- scale and long-term follow-up studies are needed to confirm the significance of miR-203 in gastric cancer.